BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, December 12, 2024
See today's BioWorld
Home
» Long Wait for Data, Galena Buys Drug to Go Commercial
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Long Wait for Data, Galena Buys Drug to Go Commercial
March 25, 2013
By
Brian Orelli
No Comments
Galena Biopharma Inc. has a bit of a wait ahead of it. The biotech initiated a Phase III trial testing NeuVax (nelipepimut-S) as an adjuvant breast cancer treatment at the beginning of 2012.
BioWorld
